The present invention is directed to novel heterodimeric antibodies.

The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.

Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

The invention relates to agonistic anti-MET antibodies and uses thereof in the therapeutic treatment of disease. The antibodies bind with high affinity to the human and mouse hepatocyte growth factor (HGF) receptor, also known as MET, and are agonists of MET in both humans and mice, producing molecular and cellular effects resembling the effects of HGF binding.

The present invention relates to the use of a CD24 protein for preventing or treating Graft versus Host Disease and mucositis.

Provided are methods for treating pemphigus using an FcRn antagonist such as efgartigimod. The methods of the invention provide a rapid onset of action to enable early disease control and maintenance of clinical remission, with or without a minimal dose of corticosteroids.

The invention provides novel heterodimeric proteins including heterodimeric antibodies.

The present invention is directed to novel heterodimeric antibodies.

The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.

IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.